Published in Sci Rep on January 15, 2015
Adding new chemistries to the genetic code. Annu Rev Biochem (2010) 6.32
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
On the attribution and additivity of binding energies. Proc Natl Acad Sci U S A (1981) 4.44
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res (2004) 3.16
Antibody-drug conjugates in cancer therapy. Annu Rev Med (2012) 2.41
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Antibody-based immunotherapy of cancer. Cell (2012) 1.35
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
Optimization of tether length in nonglycosidically linked bivalent ligands that target sites 2 and 1 of a Shiga-like toxin. J Am Chem Soc (2003) 1.19
Immunotoxins: the role of the toxin. Toxins (Basel) (2013) 1.13
Design of artificial transcriptional activators with rigid poly-L-proline linkers. J Am Chem Soc (2002) 1.09
Exact analysis of ligand-induced dimerization of monomeric receptors. Anal Chem (2008) 1.06
Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. Proc Natl Acad Sci U S A (2013) 1.04
Structure-guided deimmunization of therapeutic proteins. J Comput Biol (2013) 1.04
Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc (2002) 1.00
Dependence of avidity on linker length for a bivalent ligand-bivalent receptor model system. J Am Chem Soc (2011) 0.97
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother (2009) 0.96
Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase. Mol Pharm (2009) 0.93
Thermodynamics of multivalent interactions: influence of the linker. Langmuir (2010) 0.93
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs (2013) 0.93
Observation and characterization of the interaction between a single immunoglobulin binding domain of protein L and two equivalents of human kappa light chains. J Biol Chem (2003) 0.84
Influence of spacer-receptor interactions on the stability of bivalent ligand-receptor complexes. J Phys Chem B (2012) 0.80